Neurofeedback: fMRI neurofeedback training of amygdala downregulation
Study summary
This is a proof-of-concept study that aims to test the additional value of adjuvant neurofeedback treatment for psychotherapy. Three sessions of real-time fMRI neurofeedback will be administered to N=22 patients with BPD while they receive residential Dialectical Behavior Therapy treatment. In addition, outcomes are assessed from a control group with same sample size who do not receive the treatment.
Eligibility
Sex
ALL
Min age
18 Years
Max age
50 Years
Healthy volunteers
No
Inclusion Criteria:
* DSM-5 BPD diagnosis
* informed consent
* EtOH and tox negative on the day of neurofeedback
* BSL-23 score \>=1.87 at DBT halftime
Exclusion Criteria:
* pharmacotherapy with opiates
* standing benzodiazepines (bedtime-only benzodiazepines and anti-histamines allowed)
* pregnancy
* epilepsy
* life-time diagnosis schizophrenia or bipolar disorder I
* significant current or past neurological illness
* BMI\<16.5
* usual safety criteria for magnetic resonance imaging
Primary outcome measure(s)
Change in affective instability — Before treatment, immediately after treatment + follow-up measure (3 months) Mean successive squared differences (MSSD) of six-item negative affect scale measured via behavioural sampling using ecological momentary assessment (EMA) over four days. MSSD will be compared between baseline and post-treatment timepoints.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
